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SUMMARY
Objective: To evaluate the clinical efficacy and safety 
of a tea bag formulation of the root of C. sanguinolenta
Design: This is a prospective descriptive open trial.
Setting: Patients were recruited from Korle-Bu, 
Mamprobi and Dansoman Polyclinics. 
Subjects: Forty-four subjects with uncomplicated 
malaria were recruited for the study.
Method: Patients presented with clinical symptoms of 
malaria.  Laboratory investigations conducted included 
malaria parasite counts, haematological indices and 
biochemical tests which were obtained before, during 
and after a 5-day treatment period, up to Day 28 post-
treatment.  All patients in the study were symptomatic 
with significant parasitaemia.  Patients were given one 
teabag three times a day, that is, morning, noon and 
night, for five days of treatment. 
Results: Fifty percent of the patients were cleared of 
their P. falciparum parasitaemia by 72 hours, and all by 
Day 7.  Presenting symptoms of fever, chills, nausea 
and vomiting cleared rapidly, all by Day 3, but 
resolution of haematological and biochemical 
abnormalities associated with malaria was generally 
slow, a feature seen in malaria post-treatment.  The 
overall cure rate was 93.5% due to two cases of 
recrudescence on Days 21 and 28.  The laboratory 
findings did not suggest any toxicity.  
Conclusion: On the basis of fever clearance and 
disappearance of parasitaemia by Day 7, the formula-
tion has been shown to be non-toxic and highly 
effective in the treatment of acute uncomplicated 
malaria.
Keywords: Clinical efficacy, Cryptolepis 
sanguinolenta, falciparum malaria, Ghana, tea bag 
formulation.
INTRODUCTION
Cryptolepis sanguinolenta (Landl.) Schlecter syn 
Pergularia sanguinolenta Lindl., (Asclepiadaceae), 
which is indigenous to Africa1, grows wild as a thin-
stemmed twining and scrambling shrub along the west 
coast of Africa.2  The root and root bark decoction of 
C. sanguinolenta has been used by traditional medical 
practitioners to treat a number of diseases including 
malaria.3,4,5,6,7,8,9  Although herbal preparations have 
been used for generations for the treatment of fevers 
including malaria, there have been very little 
systematic scientific and clinical studies of most of 
these preparations.  However, a number of scientific 
studies on preparation of C. sanguinolenta have 
appeared in the literature.  Crude extracts of C. 
sanguinolenta and their fractions, as well as 
indoquinoline alkaloids isolated from the plant, have 
been shown to have activity against Plasmodium 
falciparum both in vitro and in vivo.9-13  In addition to 
studies indicating anti-plasmodial effect, extracts of C. 
sanguinolenta have been shown to have anti-microbial 
activity3,6,14-21, to be anti-hyperglycaemic22,23 and anti-
inflammatory.24  
A preliminary study of the clinical efficacy of an 
aqueous extract of C. sanguinolenta as an anti-malarial 
preparation had been carried out which indicated the 
efficacy of the extract against falciparum malaria.25  In 
that study, which was aimed at comparing efficacy of 
the aqueous extract with chloroquine, the modified 
WHO extended 7 days in vivo test26 was used to 
measure P. falciparum response in a number of 
malarial patients with parasitaemia of 1,000 to 100,000 
P. falciparum parasites per 8000 white blood cells.  
The results of this open, randomized, comparative 
study indicated that the efficacy of C. sanguinolenta in 
the treatment of falciparum malaria was comparable to 
that of chloroquine.  All the 22 patients in the study 
responded clinically and asexual parasitaemia was 
cleared within 7 days.  There was no recrudescence of 
parasitaemia during the follow-up period of 28 days.  
There are a number of herbal preparations for the 
treatment of malaria on the Ghanaian market and most 
of these are in the form of aqueous decoctions, many of 
them preserved with chloroform. Chloroform is 
hepatotoxic and therefore, its use has generally been a 
matter of concern to many Ghanaian health 
professionals.  
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Thus the formulation of an herbal preparation which 
avoids the use of preservatives is an advantage.  
PHYTO-LARIA® is a teabag formulation of C. 
sanguinolenta dried root, with flavouring and without 
any preservatives.  Even though the clinical efficacy of 
C. sanguinolenta aqueous extract had been established, 
it was necessary to confirm the clinical efficacy of C. 
sanguinolenta in the new formulation and in the dose 
prescribed. This study was undertaken to evaluate the 
clinical efficacy and safety of PHYTO-LARIA® as 
prescribed in the treatment of symptomatic 
uncomplicated malaria in semi-immune patients.
METHODS
Patients
Patients aged between 11 and 50 years, with clinical 
features of uncomplicated malaria were recruited into 
the study. They were screened using thick and thin 
blood films and those with parasitaemia of between 
1000 and 1000,000 P. falciparum per 8000 white blood 
cells were selected.  Patients with complicated malaria, 
(severe anaemia or cerebral malaria), as well as 
pregnant and lactating women, were excluded from the 
study. Patients who had taken therapeutic doses of 
chloroquine within the previous 14 days, or 
sulfadoxine/pyremethamine within 28 days were also 
excluded. Urine screening tests for chloroquine and 
sulfadoxine/pyremethamine were carried out on all 
patients before treatment on day 0 and at each follow-
up on days 1, 2, 3, 7, 14, 21 and 28.  Subjects who 
tested positive at any time were excluded from the 
study.  Consent was obtained from all the patients who 
opted to participate in the study.  Parental consent was 
obtained for young patients and supervision requested 
in order to improve compliance.  The study was cleared 
by the Ethical and Protocol Review Committee of the 
University of Ghana Medical School, where the study 
was based.
Test drug
The test drug used for treatment in this study was a tea-
bag formulation of C. sanguinolenta root powder.  
Each teabag contained 2.5 g of the root powder, plus 
flavourings.  The dose given was one teabag three 
times a day, that is, morning, noon and night, for five 
days of treatment.
Study plan
Patients were recruited from three different out-patient 
clinic sites.  This was an out-patient study carried out 
between the months of September and December 2001.  
The WHO extended 7-day in vivo test26 was used to 
measure P. falciparum response to the formulation.
Patients admitted to the study had their medical history 
taken and physical examination conducted before 
treatment started (D0) and on each of the follow-up 
days (Days 1, 2, 3, 7, 14, 21 and 28). Body 
temperature, pulse rate, blood pressure and respiratory 
rate were measured on each visit.  The type of malaria 
was diagnosed by examination of thick and thin blood 
films and malaria parasite count performed. Parasite 
counts were repeated during treatment on Days 1, 2 
and 3, and subsequently on Days 7, 14, 21 and 28.
In order to assess the efficacy of the formulation the 
following parameters were measured or derived: 
parasite clearance time, fever resolution time and 
recrudescence within the 28 days follow up. The 
treatment was considered curative if there was 
clearance of falciparum parasitaemia by Day 7 and no 
recrudescence during the 28-day follow up period.  
Fever was defined as axilla temperature above 37.50C, 
and the fever clearance time as the time in hours until 
the body temperature fell to 370C or less and remained 
below 37.50C for 24 hours.  Improvement in physical 
signs and symptoms, such as body ache, nausea, 
dizziness and headache, were also included in the 
evaluation criteria for efficacy.
The following haematological tests, including 
haemoglobin (Hb), haematrocrit, reticulocyte count, 
total white cell count (WBC), platelet count 
(Automated Haematology Analyzer, Sysmex KX-21, 
Kobe, Japan) and erythrocyte sedimentation rate (ESR) 
were done before treatment and on Days 3, 7, 14, 21 
and 28 after starting treatment.  Biochemical tests 
carried out using semi-automated clinical chemistry 
analyzer (Microlab 300, Vital Scientific N.V., The 
Netherlands) included serum urea and creatinine, 
bilirubin both total and direct, as well as the enzymes 
aspartate aminotransferase (ASAT), alanine 
aminotransferase (ALAT) and alkaline phosphatase 
(ALP) were measured before, during and after 
treatment.  In addition, serum uric acid, glucose, total 
proteins and total cholesterol were also measured. 
Urinalysis for glucose, albumin, blood, urobilinogen, 
bilirubin and urinary sediment examination were 
conducted on all the observation days. The clinical and 
laboratory findings, as well as suspected adverse drug 
reactions were recorded on standard forms.
Data analysis
Data was analyzed using SPSS (Version 10.0). Results 
are presented as mean (+SD) or as proportions as 
appropriate.  More than two means were compared 
using one-way ANOVA with appropriate pairwise post 
hoc t-tests for isolating groups that were statistically 
significant.  p values less than 0.05 were considered 
significant.




Forty-four patients (22 males and 22 females) with 
acute uncomplicated malaria entered the study. Their 
mean age was 25.2 (9.2) years and their mean body 
weight of 60.1 (14.6) kg.  By the 7th day, 12 patients 
had defaulted and one other patient was withdrawn 
following the development of upper respiratory 
infection, diarrhoea and fainting episode.  Thirty-one 
patients, therefore, completed the study. All patients in 
the study were symptomatic with significant 
parasitaemia ranging from 924 to 264, 857 per µl of 
blood (geometric mean = 20892).
  Only one patient in the study had less than 103
parasites per µl of blood initially and 2 patients had 105
parasites per µl of blood.  The rest had between 103 and 
105 parasites per µl of blood (Table 1).
More than 50% of patients were cleared of their P. 
falciparum parasitaemia by 72h. The mean parasite 
clearance time was 82.3 (39) h. All the patients 
evaluated had cleared by Day 7 and, except for two, 
remained so throughout the rest of the 28 days.  There 
were 2 cases of recrudescence, one occurring on Day 
21 and the other on Day 28. The mean initial 
temperature of the patients in the study was 38.430C.  
The mean fever clearance time was 25.2 (21.2) hours.
Clinical data
Table 2 shows the incidence and duration of presenting 
symptoms. The commonest presenting symptom was 
body ache followed by fever, chills, headache, 
weakness, nausea, vomiting, and abdominal pains.  The 
fever, chills, nausea and vomiting cleared rapidly, all 
by Day 3, whereas the headaches, body ache, weakness 
and abdominal pains presented in diminishing number 
of patients.
Clinical jaundice was noticed in 4 patients before 
treatment, clearing in all of them by Day 7 post-
treatment.  Hepatomegaly was observed in 4 patients, 
resolving in 3 patients by Day 7, and persisting post-
treatment in one patient whose condition was severe.




Number of parasites /  µl of blood Number of patients
cleared (cumulative)
<103 103  -  104 104 - 105 >105 Total %
24 0 1 3 0 4 12.9
48 0 1 6 0 11 35.4
72 0 2 4 1 18 58.1
96 0 0 5 0 23 74.1
120 0 1 1 0 25 80.6
144 1 4 0 1 31 100
Table 2 Evolution of presenting symptoms following treatment with PHYTOLARIA®. 
Numbers represent patients expressed as percentage.
Symptom Day
0 1 2 3 7 14 21 28
Abdominal Pain 60.9 34.4 45.2 19.4 6.45 9.7 9.7 3.2
Body – ache 95.6 37.5 29.0 9.7 3.2 3.2 3.2 3.2
Chills 93.3 25.0 12.9 3.2 0 0 0 0
Diarrhoea 13.0 6.25 6.25 9.7 3.2 6.25 3.2 3.2
Dizziness 58.7 34.4 32.2 16.1 3.2 0 0 0
Fever 93.3 25.0 12.9 3.2 0 0 0 0
Hallucinations 17.4 9.4 3.2 0 6.25 0 0 0
Headache 93.3 68.7 58.1 48.4 25.8 25.8 16.1 6.25
Nausea 76.0 21.9 35.5 16.1 0 0 0 0
Skin Itch 2.2 3.1 6.45 0 3.2 0 0 0
Vomiting 58.7 9.4 32.2 9.7 0 0 0 0
Weakness 91.3 53.1 35.5 16.1 19.4 9.7 6.25 9.7
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Table 3 Patients’ haematological parameters for the experimental period. Values are   means + S.D.
Haematological. Day of Experimental Period
Parameter 0 3 7 14 21 28
Haemoglobin (g/dl)
Male [17] .7±1.7 12.1±1.4 11.7±1.0 11.8±0.9 2.0±1.1 12.5±1.0
Female [14] 11.8±1.4 10.9±1.6 10.4±1.6 11.0±1.3 11.5±1.3 11.6±1.6
Haematocrit
Male [17] 0.38±.05 0.37±.03 0.36±.0.6 0.36±.03 0.37±.03 0.38±.04
Female [14] 0.36±.04 0.34±.05 0.36±.06 0.36±.03 0.37±.03 0.38±.04
ESR (mm/h)
Male [16] 44.8±30.7 56.4±34.1 55.8±24.5 55.6±33.5 51.3±27.3 52.9±38.2
Female [13] 67.2±35.0 54.3±38.1 92.6±46.0 78.2±23.8 64.3±30.1 56.7±25.9
Total WBC (x109/L) [31] 7.9±3.7 5.4±1.5 5.8±1.5 6.1±1.7 5.9±2.0 6.3±1.6
Platelet(x 1010/L0 [31] 18.7±9.9 20.3±18.4 27.1±12.9 32.2±10.8 29.3±11.9 26.4±9.1
Reticulocyte (%) [25] 1.85±.60 1.78±.48 1.89±56 1.80±.49 1.70±.36 1.84±.35
Table 4 Biochemical parameters for patients for the experimental period. Figures in square parentheses represent 
number of patients. Values are means + S.D. 
Biochemical Day of Experimental Period
Parameter 0 3 7 14 21 28
Creatinine (umol/L
   [30]    88.9±14.9 85.4±11.6 96.6±50.3 72.8±16.2 75.0±13.8 82.5±19.6
Urea (umol/L)
  [30] 4.94±1.65 4.91±2.62 3.87±1.51 3.52±1.22 3.85±1.42 4.69±2.03
Aminotransferases (u/L)
  ASAT [30] 21.3±9.4 30.1±23.9 27.8±13.1 27.2±17.3 25.3±15.4 28.8±14.6
ALAT [30] 7.2±6.3 7.9±7.7 10.3±8.7 7.3±7.3 6.7±4.4 6.5±2.3
Alkaline Phosphatase (u/L)
[30] 84.5±56.2 95.7±63.3 90.0±47.1 132.2±61.4 102.8±84.6 125.8±76.1
Bilirubin (umol/L
Total [30]      12.4±6.5 16.4±9.1 17.9±2.9 15.0±7.1 17.7±8.0 15.1±6.2
Direct [30] 5.1±2.9 7.2±2.9 7.5±2.2 6.5±2.7 5.4±3.2 7.7±2.8
Total proteins (g/L)
[30]      77.2±4.3 69.5±5.4 70.0±9.0 75.0±6.7 76.9±6.7 81.6±4.1
Total Cholesterol, random (umol/L)
[30] 4.02±.98 3.60±.63 3.33±1.06 4.51±.92 4.18±.91 2.92±.86
Glucose (umol/L)
[30] 6.03±1.07 5.68±.98 5.32±.96 5.39±.81 5.29±.81 5.58±2.80
Uric Acid (umol/L x 100)
Male [16] 2.19±.69 4.31±1.05 4.17±1.54 2.64±1.08 2.55±.82 3.73±.84
Female [14] 2.12±.69 3.69±1.09 3.04±1.05 2.90±1.01 1.90±.27 2.95±.41
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Laboratory data
The haematological data is presented in Table 3. The 
mean haemoglobin levels were lower during treatment, 
compared to pretreatment values, but started to rise by 
Day 14, approaching pre-treatment levels by Day 28. 
Total WBC count dropped from the pre-treatment level 
and remained low throughout the 28-day study period 
although the post-treatment values were higher than the 
values during treatment. Platelet count increased 
progressively with treatment, from a low pre-treatment 
value to upper normal values and began to decline after 
Day 14.  ESR, haematocrit and reticulocyte counts 
showed little change from the pre-treatment values 
with treatment.
The majority of biochemical parameters in the patients 
were not significantly modified following treatment 
(Table 4). All mean values determined for creatinine 
and urea, which reflect renal function, were within the 
range considered as normal. Of the indices of liver 
function, both total and direct bilirubin appeared 
elevated compared to pre-treatment values but the 
levels were all within the range considered normal.  
Alkaline phosphatase (ALP) levels were persistently 
elevated throughout the study period compared to the 
pre-treatment values, with peak levels on Day 14.  
There were no significant differences in the two
aminotransferases measured (ASAT and ALAT), 
although the values were generally higher during and 
after treatment.  Level of total protein and glucose did 
not change significantly with treatment.  Total 
cholesterol level dropped during treatment rose on Day 
14 and was again significantly lower than pre-treatment 
values by Day 28.
Serum uric acid levels showed a significant rise during 
treatment (Day 3) and remained higher than pre-
treatment values until the last week of the study period.
Statistical comparison of the various parameters 
yielded p-value > 0.05 in all cases.  This implies that 
there was no statistical significant difference between 
the effect of the drug and the normal state.
DISCUSSION
This open study was designed to investigate the clinical
efficacy of the tea-bag formulation of C. sanguinolenta
root powder for the treatment of acute uncomplicated 
falciparum malaria in a Ghanaian population. The 
overall cure rate was 93.5%.  There were two cases of 
late recrudescence on Days 21 and 28.  These could be 
due to re-infection as this was an out-patient study.
In this study the mean parasite clearance time was 
82.3h and the fever clearance time was 24.5h.  These 
values are comparable to the ones obtained in the 
preliminary clinical study when C. sanguinolenta
aqueous extract was used.  In the study comparing the 
efficacy of aqueous extract of C. sanguinolenta to that 
of chloroquine, the parasite and fever clearance times 
for the patients on chloroquine were 56h and 48h 
respectively. C. sanguinolenta was better at fever 
clearance than chloroquine.  In addition, unlike patients 
in the chloroquine treated group, patients in the 
cryptolepis treated group did not require antipyretics.  
The short fever clearance time for PHYTO-LARIA® in 
this study is likely due to the antipyretic property 
reported for C. sanguinolenta.27,28
From the results of the evolution of presenting 
symptoms shown in Table 2, one could regard the 
symptoms with a very high incidence (>90%) as the 
ones which are characteristic of falciparum malaria.  
These were body ache, chills, fever, headache and 
weakness.  Of these, chills and fever cleared rapidly in 
all patients and were completely resolved by Day 7 
when the parasitaemia cleared.  The other symptoms 
are those related to pain and they persisted in some 
patients throughout the experimental period.  
Approximately 25% of the patients still had headaches 
on Day 7 when they had no parasites in the blood.
A number of abnormalities in laboratory values in 
haematology and biochemistry were present before 
treatment. The resolution of these abnormalities post-
treatment was slow generally. This is a feature 
commonly seen in malaria post-treatment. For 
example, the haemoglobin pattern showed the usual 
low levels of the protein, contributing to weakness, one 
of the most persistent symptoms post-treatment.  
Thrombocytopenia is frequently associated with acute 
malaria. Therefore, the progressive increase in platelet 
count after treatment could be regarded as indicative of 
the effectiveness of the test drug against falciparum 
malaria. The persistence of alkaline phosphatase 
elevation has been noted with halofantrine29.  The 
laboratory findings do not suggest toxicity of the test 
drug, although a recent publication suggests that the 
herb can be genotoxic to mammalian cells30. It has also 
been found to induce dose-dependent anxiety in mice.31
There is evidence of chloroquine resistance in Ghana32
hence drugs such as artesunate-amodiaquine 
combination have replaced chloroquine for malaria 
treatment. C. sanguinolenta and the indoquinoline 
alkaloids isolated from it have been shown to be 
effective against chloroquine-resistant strains of the 
parasite.9,10,12
Therefore, although chloroquine resistance was not part 
of the study, the high cure rate reported would tend to 
suggest that the tea bag formulation of the root powder 
of C. sanguinolenta could be used for the treatment of 
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malaria caused by chloroquine-resistant strain of P. 
falciparum.
Evaluated on evidence of fever clearance and 
disappearance of parasitaemia by Day 7, according to 
the modified WHO criteria, the tea bag formulation of 
the root powder of C. sanguinolenta has been shown 
to be highly effective in the treatment of acute 
uncomplicated malaria.
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